Kerdel Francisco A, Strober Bruce E
Professor of Dermatology and Vice Chairman, Florida International University, Miami, Florida.
Associate Professor and Vice Chair, University of Connecticut Health Center, Farmington, Connecticut.
Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S31-6. doi: 10.12788/j.sder.0066.
Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA). This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.
目前有三种肿瘤坏死因子（TNF）抑制剂被批准用于治疗银屑病：依那西普、英夫利昔单抗和阿达木单抗。另外两种TNF抑制剂，戈利木单抗和聚乙二醇化赛妥珠单抗，在银屑病关节炎（PsA）的临床试验中已显示出对斑块状银屑病有效。本文综述了TNF抑制剂治疗银屑病疗效和安全性的最新证据，特别关注免疫原性的预防和管理。
